Evidence map›Paper›PMID 42080109›Full record

ArticleAvicenna journal of medical biotechnology2026

Expression, Purification, and Application of SARS-CoV-2 Nucleocapsid Protein for Serological Detection of IgG and IgM Antibodies.

Saeideh Zamani Koukhaloo, Farshid Moosavi, Bahareh Zamani, Niloofar Agharezaee, Parisa Yousefi, Mahboobeh Nazari, Jafar Mahmoudian

Abstract read
In one paragraph

Article in Avicenna journal of medical biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Saeideh Zamani KoukhalooMonoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
Farshid MoosaviMonoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
Bahareh ZamaniMonoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
Niloofar AgharezaeeMonoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
Parisa YousefiMonoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
Mahboobeh NazariMonoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
Jafar MahmoudianMonoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: SARS-CoV-2 is a novel coronavirus that has caused dramatic loss of life and poses an unprecedented public health challenge worldwide. The nucleocapsid (N) protein of SARS-CoV-2 is the most abundant viral protein and a potent immunogen. Methods: In the current study, the Results: The results showed that purification of the N protein in the presence of urea yielded a protein band of approximately 48 Conclusion: These results indicate that the expressed N protein of SARS-CoV-2 could serve as a valuable reagent for the development of antibody-based immunoassays to detect SARS-CoV-2 IgG and IgM antibodies.

Indexed as

ELISANucleocapsid (N) proteinRecombinant protein expressionSARS-CoV-2Serological diagnosis

Identifiers

PMID42080109
PMCPMC13134675

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.